Scinai Immunotherapeutics Ltd.
SCNI
$2.54
-$0.04-1.55%
NASDAQ
| 06/30/2023 | 03/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -4.20% | -34.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.55% | -52.72% | |||
| Operating Income | 18.55% | 52.72% | |||
| Income Before Tax | -7.03% | -564.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.03% | -564.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.03% | -564.71% | |||
| EBIT | 18.55% | 52.72% | |||
| EBITDA | 19.69% | 53.80% | |||
| EPS Basic | -2.55% | -298.95% | |||
| Normalized Basic EPS | -2.55% | -298.97% | |||
| EPS Diluted | 0.00% | -2.58% | |||
| Normalized Diluted EPS | -2.55% | -298.97% | |||
| Average Basic Shares Outstanding | 4.39% | 66.56% | |||
| Average Diluted Shares Outstanding | -- | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||